MOGANSHAN
Live / Registered — Registered (as of 19 Mar 2024)
What this means for you
Registered since 19 Mar 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79344895
- Registration number
- 7330063
- Mark type
- Design + words
- Filed
- 14 Jun 2022
- Published for opposition
- 02 Jan 2024
- Registered
- 19 Mar 2024
- Attorney of record
- Prakash NAMA
Goods and services
- Class 005 — Pharmaceuticals: Drugs for medical purposes, namely, adjuvant treatment of myocardial ischemia, shock, hypoxia, and tissue damage; Drugs for medical purposes, namely, antivirals for the treatment of acute zoster, incipient and recurrent genital herpes, and chickenpox; Drugs for medical purposes, namely, antivirals suitable for treating viral pneumonia caused by respiratory syncytial virus, bronchitis, and skin herpes virus infection, in combination with interferon alpha for the treatment of chronic hepatitis C in adults; Drugs for medical purposes, namely, anticancer preparations for choriocarcinoma, malignant mole, acute lymphoblastic leukemia and acute non-lymphoblastic leukemia, and acute stage of chronic granulocytic leukemia; Drugs for medical purposes, namely, antiallergic medicine for the treatment of seasonal rhinitis, perennial allergic rhinitis, allergic conjunctivitis and allergy-induced pruritus and urticaria; Antibiotics; Drugs for medical purposes, namely, adjuvant treatment of acute and chronic hepatitis; Pharmaceutical preparations, namely, adjuvant treatment of myocardial ischemia, shock, hypoxia, and tissue damage; Pharmaceutical preparations, namely, antivirals for the treatment of acute zoster, incipient and recurrent genital herpes, and chickenpox; Pharmaceutical preparations, namely, antivirals suitable for treating viral pneumonia caused by respiratory syncytial virus, bronchitis, and skin herpes virus infection, in combination with interferon alpha for the treatment of chronic hepatitis C in adults; Pharmaceutical preparations, namely, anticancer for choriocarcinoma, malignant mole, acute lymphoblastic leukemia and acute non-lymphoblastic leukemia, and acute stage of chronic granulocytic leukemia; Pharmaceutical preparations, namely, antiallergic medicine for the treatment of seasonal rhinitis, perennial allergic rhinitis, allergic conjunctivitis and allergy-induced pruritus and urticaria; Pharmaceutical preparations, namely, adjuvant treatment of acute and chronic hepatitis; Antivirals suitable for treating viral pneumonia caused by respiratory syncytial virus, bronchitis, and skin herpes virus infection in combination with interferon alpha for the treatment of chronic hepatitis C in adults; Antiallergic medicine for the treatment of seasonal rhinitis, perennial allergic rhinitis, allergic conjunctivitis and allergy-induced pruritus and urticaria; Antivirals for the treatment of acute zoster, incipient and recurrent genital herpes, and chickenpox; Anticancer preparations for choriocarcinoma, malignant mole, acute lymphoblastic leukemia and acute non-lymphoblastic leukemia, and acute stage of chronic granulocytic leukemia
Owner
Prosecution history
- 11 Aug 2024 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 21 Jul 2024 — FINAL DISPOSITION NOTICE SENT TO IB
- 21 Jul 2024 — FINAL DISPOSITION PROCESSED
- 20 Jun 2024 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 19 Mar 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 19 Mar 2024 — REGISTERED-PRINCIPAL REGISTER
- 07 Jan 2024 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 02 Jan 2024 — NOTIFICATION PROCESSED BY IB
- 02 Jan 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 02 Jan 2024 — PUBLISHED FOR OPPOSITION
- 20 Dec 2023 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 20 Dec 2023 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 13 Dec 2023 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 13 Dec 2023 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
- 13 Dec 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED